[Androgens and other hormones in buserelin therapy]

Fuchs U, U Fuchs, M. Zwirner, Zwirner M
Geburtshilfe und Frauenheilkunde · 1991 · vol. 51(02) , pp. 140–142 · doi:10.1055/s-2007-1023690 · PMID:1904040 · W2064675753
Non-randomised trial OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-14 ⓘ

Buserelin therapy for endometriosis significantly decreased LH, E2, prolactin, progesterone, and testosterone while reducing implantation scores without exerting an androgenic effect.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-14 · read from full text ⓘ

This study evaluated hormonal changes in 23 women of reproductive age diagnosed with endometriosis via laparoscopy and biopsy who received Buserelin nasal spray for six months. Serum levels of LH, estradiol, prolactin, progesterone, and testosterone decreased significantly over the treatment period, while FSH, free testosterone, and androstenedione showed only slight reductions. The researchers observed no significant changes in DHEAS or SHBG concentrations and concluded that Buserelin exerts no androgenic effect. Concurrently, the severity of endometriosis, measured by implantation scores, decreased significantly during the therapy. This paper is centrally about endometriosis — specifically the hormonal profile and efficacy of GnRH agonist therapy for the condition.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

23 women of reproductive age were treated with Buserelin nose-spray for endometriosis, which had been diagnosed by laparoscopic and bioptic methods. The treatment period was 6 months. Various hormones in serum were determined after 2, 4, 8, 12, 16, 20 and 24 weeks during treatment. LH, E2, prolactin, progesterone, and testosterone concentrations were significantly decreased under Buserelin therapy, whereas there was only a slight decrease in FSH, free testosterone and androstendion. No changes were observed in the concentrations of DHEAS and SHEBG. Buserelin had no androgenic effect. There was a significant decrease of endometriosis as judged by the implantation score.
Full text 1,557 characters · extracted from oa-doi-fallback · click to expand
Subscribe to RSS DOI: 10.1055/s-2007-1023690 Androgene und andere Hormone unter Buserelintherapie Androgens and Other Hormones during Buserelin TherapyPublication History Publication Date: 16 June 2008 (online) Zusammenfassung Das Nasenspray Buserelin wurde bei 23 Frauen im reproduktiven Alter zur Behandlung von laparoskopisch und bioptisch gesicherter Endometriose über 6 Monate eingesetzt und die hormonellen Veränderungen unter dieser Therapie nach 2, 4, 8,12,16, 20 und 24 Wochen erfaßt. LH, E2, Prolaktin, Progesteron und Testosteron nahmen signifikant während der Buserelintherapie ab. Die mittleren Serumspiegel für FSH, freies Testosteron, Androstendion senkten sich geringfügig. DHEAS und SHBG veränderten sich nicht. Buserelin hat keine androgenisierende Wirkung. Die Endometriose nahm - gemessen am Implantatscore - signifikant unter der Buserelintherapie ab. Abstract 23 women of reproductive age were treated with Buserelin nose-spray for endometriosis, which had been diagnosed by laparoscopic and bioptic methods. The treatment period was 6 months. Various hormones in serum were determined after 2, 4, 8,12,16, 20 and 24 weeks during treatment. LH, E2, prolactin, progesterone, and testosterone concentrations were significantly decreased under Buserelin therapy, whereas there was only a slight decrease in FSH, free testosterone and androstendion. No changes were observed in the concentrations of DHEAS and SHEBG. Buserelin had no androgenic effect. There was a significant decrease of endometriosis as judged by the implantation score.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Androgens Buserelin Endometriosis Gonadal Steroid Hormones Pelvic Neoplasms Administration, Intranasal Administration, Intranasal Adolescent Adolescent Adult Adult Androgens Androgens Buserelin Buserelin Buserelin Endometriosis Endometriosis Endometriosis Estradiol

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-20T06:13:28.455750+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:05:57.285809+00:00
License: CC0 · commercial use OK